Grand Brilliance Group Holdings (HKSE:08372) ROE %: 7.60% (As of Mar. 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08372 Grand Brilliance Group Holdings Ltd HKSE:08372
66 GF Score
Price HK$0.13
GF Value HK$0.12
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Grand Brilliance Group Holdings ROE %?

Grand Brilliance Group Holdings HKSE:08372 66 ROE % is 7.60% as of Mar. 2026, which is 7% below its 10-year median of 8.18. GuruFocus rates HKSE:08372 with a GF Score™ of 66/100 and a GF Value™ of HK$0.12 (Fairly Valued). The stock has 5 warning signs investors should review. Among 115 Medical Distribution companies, Grand Brilliance Group Holdings ranks better than 52.17% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Grand Brilliance Group Holdings's annualized net income for the quarter that ended in Mar. 2026 was HK$8.7 Mil. Grand Brilliance Group Holdings's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was HK$115.0 Mil. Therefore, Grand Brilliance Group Holdings's annualized ROE % for the quarter that ended in Mar. 2026 was 7.60%.

The historical rank and industry rank for Grand Brilliance Group Holdings's ROE % or its related term are showing as below:

HKSE:08372' s ROE % Range Over the Past 10 Years
Min: -5.82   Med: 8.18   Max: 37.53
Current: 7.41

During the past 11 years, Grand Brilliance Group Holdings's highest ROE % was 37.53%. The lowest was -5.82%. And the median was 8.18%.

HKSE:08372's ROE % is ranked better than
52.17% of 115 companies
in the Medical Distribution industry
Industry Median: 7.1 vs HKSE:08372: 7.41

Grand Brilliance Group Holdings  (HKSE:08372) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=8.736/115.015
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(8.736 / 96.442)*(96.442 / 136.114)*(136.114 / 115.015)
=Net Margin %*Asset Turnover*Equity Multiplier
=9.06 %*0.7085*1.1834
=ROA %*Equity Multiplier
=6.42 %*1.1834
=7.60 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=8.736/115.015
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (8.736 / 8.178) * (8.178 / 7.646) * (7.646 / 96.442) * (96.442 / 136.114) * (136.114 / 115.015)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0682 * 1.0696 * 7.93 % * 0.7085 * 1.1834
=7.60 %

Note: The net income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Grand Brilliance Group Holdings ROE % Related Terms


Grand Brilliance Group Holdings ROE % Historical Data

* Premium members only.

The historical data trend for Grand Brilliance Group Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grand Brilliance Group Holdings ROE % Chart

Grand Brilliance Group Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.34 7.87 7.78 8.84 7.38

Grand Brilliance Group Holdings Semi-Annual Data
Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.94 6.61 11.17 7.24 7.60

HKSE:08372 vs MCK, COR, CAH: ROE % Comparison

For the Medical Distribution subindustry, Grand Brilliance Group Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grand Brilliance Group Holdings ROE % vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Grand Brilliance Group Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Grand Brilliance Group Holdings's ROE % falls into.


HKSE:08372
66GF Score
Grand Brilliance Group Holdings Ltd HKSE:08372
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grand Brilliance Group Holdings ROE % Calculation

Grand Brilliance Group Holdings's annualized ROE % for the fiscal year that ended in Mar. 2026 is calculated as

ROE %=Net Income (A: Mar. 2026 )/( (Total Stockholders Equity (A: Mar. 2025 )+Total Stockholders Equity (A: Mar. 2026 ))/ count )
=8.413/( (110.786+117.199)/ 2 )
=8.413/113.9925
=7.38 %

Grand Brilliance Group Holdings's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Sep. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=8.736/( (112.831+117.199)/ 2 )
=8.736/115.015
=7.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 7.60% mean?
Grand Brilliance Group Holdings (HKSE:08372) has a ROE % of 7.60% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Grand Brilliance Group Holdings and its competitors. This is near median its historical median of 8.18. According to the industry distribution chart, Grand Brilliance Group Holdings ranks #55 out of 115 companies in the Medical Distribution industry, placing it in the top 47.8%.
Is Grand Brilliance Group Holdings' ROE % too high?
Grand Brilliance Group Holdings' current ROE % of 7.60% is near median its 10-year median of 8.18. The Medical Distribution industry median ROE % is 7.10. Grand Brilliance Group Holdings' value of 7.60% is 7% above this industry median. Based on the distribution chart, Grand Brilliance Group Holdings ranks #55 out of 115 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Grand Brilliance Group Holdings has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Grand Brilliance Group Holdings' ROE % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Grand Brilliance Group Holdings ranks #55 out of 115 companies for ROE %. This puts Grand Brilliance Group Holdings in the upper half of its industry. The industry median ROE % is 7.10. Grand Brilliance Group Holdings' value of 7.60% is 7% above this benchmark. While the company's 10-year median is 8.18 vs. the industry median of 7.10, Grand Brilliance Group Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Distribution company?
The median ROE % among Medical Distribution companies is 7.10, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Brilliance Group Holdings's current ROE % of 7.60% is 7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Grand Brilliance Group Holdings and its competitors. For the Medical Distribution industry, the median ROE % is 7.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Brilliance Group Holdings's current ROE % is 7.60%, which is near median its own 10-year median of 8.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Brilliance Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Grand Brilliance Group Holdings (HKSE:08372) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.12, compared to a current price of HK$0.13 — trading 5.8% above its estimated fair value. The current ROE % is 7.60%, which is near median its 10-year median of 8.18 and 7% above the Medical Distribution industry median of 7.10. Grand Brilliance Group Holdings' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Grand Brilliance Group Holdings (HKSE:08372), the current ROE % is 7.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grand Brilliance Group Holdings (HKSE:08372) Overvalued in 2026?

Based on GuruFocus' analysis, Grand Brilliance Group Holdings stock appears to be overvalued. The current stock price of HK$0.13 is trading 5.8% above its estimated GF Value™ of HK$0.12. GuruFocus considers Grand Brilliance Group Holdings to be Fairly Valued.

Key valuation signals for HKSE:08372:

  • ROE %: 7.60% (near median its 10-year median of 8.18)
  • GF Value™: HK$0.12 vs. price of HK$0.13 (5.8% above fair value)
  • GF Score™: 66/100 with 5 warning signs
  • Industry Position: 7% above the Medical Distribution median (#55 of 115)

No single metric tells the full story. See the HKSE:08372 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Grand Brilliance Group Holdings Business Description

Address 6 Sha Tsui Road, The Octagon, Units 2901-2903 and 2905, 29th Floor, New Territories, Tsuen Wan, Hong Kong, HKG
Grand Brilliance Group Holdings Ltd is an investment holding. The company is engaged in the business of medical device distribution. The company also provides one-stop medical device solutions, including market trend analysis, sourcing of medical devices, after-sale services, technical support, and training services, medical device leasing services, and quality assurance. Geographically, the company derives revenue from Hong Kong. It serves private hospitals, public hospitals, private clinics, non-profit organizations, universities, and individual end-users in Hong Kong.
66GF Score

Get the complete analysis for HKSE:08372

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.13
Price
HK$0.12
GF Value